Overview of the drug development pipeline for urinary incontinence therapeutics

Damage in the pelvic floor muscles and the urethral sphincter or weak bladder nerve can lead to the unintentional passing of urine, which is known as urinary incontinence. Several research studies have shown that pregnancy and childbirth could damage or weaken the pelvic floor muscles, which can lead to urinary incontinence in women. Obesity is another factor that can cause urinary incontinence in both men and women. The prevalence of urinary incontinence in the older population is high owing to chronic diseases such as Alzheimer’s disease, Parkinson’s disease, diabetes, and anxiety. Such chronic diseases can weaken the bladder nerves and muscles, which, in turn, lead to urinary incontinence. According to the NIH report in June 2018, one in three older men has the problem of unintentional or accidental passing of urine in the US. Furthermore, growing interest in cell therapy-based drugs is emerging, which can help to regain the urinary control by regenerating the damaged urethral muscle. Therefore, companies such as Cook MyoSite developed a therapeutic molecule known as AMDC-USR for the treatment of stress urinary incontinence. As a result, increasing incidences of the disease are further expected to boost the drug development for urinary incontinence therapeutics over the forthcoming years.

According to this pipeline analysis report, most of the drug molecules in the pipeline are being developed for stress urinary incontinence. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of urinary incontinence therapeutics. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are –

• Allergan
• Beech Tree Labs
• Cytori Therapeutics
• Ipsen

Therapeutic assessment of the drug development pipeline for urinary incontinence therapeutics by route of administration

• Oral
• Intradetrusor injection
• Intramuscular injection
• Parenteral
• Periurethral injection
• Sublingual
• Transurethral intrasphincteric injection

The oral route of administration (ROA) involves the application of the drug directly into the mouth cavity, which will have a more direct effect on the target cells.

Therapeutic assessment of the drug development pipeline for urinary incontinence therapeutics by therapy

• Monotherapy

According to this pipeline analysis report, all the molecules that are currently in the drug development pipeline for urinary incontinence therapeutics are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.

Key questions answered in the report include

• What are the gene therapy molecules in the various development stages for urinary incontinence therapeutics?
• What are the companies that are currently involved in the development of gene therapy molecules for urinary incontinence therapeutics?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.